Altaris to acquire Simulations Plus in $375m all-cash deal

Simulations Plus has entered a definitive statement to beryllium purchased by affiliates of Altaris successful an all-cash transaction valued astatine astir $375m.

Under the deal, Simulations Plus shareholders volition person $18.50 per share, representing a 26% premium to the 60-day volume-weighted mean terms arsenic of 15 June 2026.

The company's committee of directors unanimously approved the acquisition, which remains taxable to customary closing conditions, including shareholder and regulatory approvals. Completion of the transaction is expected successful the 4th fourth of 2026.

Altaris plans to harvester Simulations Plus with Chemical Computing Group (CCG), a institution successful its portfolio. CCG provides precocious molecular plan bundle for clients successful the pharmaceutical, chemic and materials sectors.

The operation aims to physique a much broad biosimulation level for cause find and development, supporting customers passim the full probe and improvement beingness cycle.

Following the closing of the acquisition, Simulations Plus is expected to go a privately held subsidiary of Altaris. The company's main bureau volition stay successful Research Triangle Park, North Carolina.

Once the process is finalised, Simulations Plus' shares volition beryllium delisted from the Nasdaq Stock Exchange.

Simulations Plus develops model-informed and AI-driven cause improvement software.

Its platforms, including GastroPlus, the Monolix Suite, ADMET Predictor, and the quantitative systems pharmacology/quantitative systems toxicology (QSP/QST) platform, are wide utilized by ample pharmaceutical companies, declaration probe organisations, and regulatory agencies.

CCG's flagship product, the molecular operating environment, has been adopted successful the planetary biopharma assemblage for much than 30 years.

Simulations Plus CEO Shawn O'Connor said: "The beingness sciences manufacture is astatine an inflexion point, arsenic bundle and services are rapidly evolving toward integrated, AI-driven platforms, cloud-based infrastructure, and much predictable, subscription-based concern models.

"This transaction provides contiguous and definite worth to Simulations Plus stockholders, and we judge the transaction volition amended presumption america to service our customers and accelerate innovation crossed merchandise offerings."

Financial and ineligible advisers for the transaction see Morgan Stanley and Procopio Cory Hargreaves & Savitch for Simulations Plus, alongside Truist Securities; JP Morgan Securities; Bass, Berry & Sims; and Kirkland & Ellis for Altaris.

In March 2026, Simulations Plus announced strategical concern programmes with 3 pharmaceutical businesses to beforehand AI-enabled modelling successful cause development.

"Altaris to get Simulations Plus successful $375m all-cash deal" was primitively created and published by Hospital Management, a GlobalData owned brand.